Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported multiple new data sets for its MC4R agonists setmelanotide and oral bivamelagon in acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS) and Prader-Willi syndrome (PWS) at ENDO 2026.
Highlights include long-term BMI reductions, weight category improvements, real-world weight loss and reduced obesity-related healthcare visits, alongside manageable adverse events.
Rhythm Pharmaceuticals (Nasdaq:RYTM) reported positive interim six‑month data from a Phase 2 trial of setmelanotide in patients with Prader‑Willi syndrome (PWS) presented at ENDO 2026.
Among 17 patients, results showed mean BMI reductions, fat mass loss with preserved lean mass, improved hyperphagia and anxiety measures, and safety consistent with the known profile, supporting advancement to Phase 3.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month Phase 2 results evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
The webcast and 30-day replay will be available in the Investor Relations section under Events and Presentations on the Rhythm Pharmaceuticals website.
Rhythm Pharmaceuticals (Nasdaq:RYTM) will feature seven abstracts, including four late-breaking, at ENDO 2026 on June 13‑16 in Chicago.
Presentations cover setmelanotide and oral bivamelagon in Prader‑Willi syndrome, acquired hypothalamic obesity, and Bardet‑Biedl syndrome, plus Rhythm’s MOMENTUM expert meeting on June 12.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced publication of a new, evidence-based diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. Developed by international experts and patient groups, the algorithm integrates updated clinical and genetic insights to support earlier, clinically based BBS diagnosis across all ages and presentations.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced management participation in two upcoming healthcare investor conferences. CFO Hunter Smith will join a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET.
CEO David Meeker will speak at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 1:20 p.m. ET. Both webcasts and 30-day replays will be accessible via the company’s Investor Relations webpage under “Events & Presentations”.
Rhythm Pharmaceuticals (Nasdaq:RYTM) will present six posters, including four with new data, on setmelanotide at the 2026 European Congress of Endocrinology in Prague.
Highlights include real-world BMI reductions in acquired hypothalamic obesity, Phase 3 cardiometabolic index improvements, underrecognized hyperphagia in Bardet-Biedl syndrome, and the lifelong burden of acquired hypothalamic obesity after craniopharyngioma.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., Chairman, President and CEO, will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13, 2026 at 3:00 p.m. PT in Las Vegas.
The event will be webcast and available under Events & Presentations in the company Investor Relations site, with a replay available on the Rhythm website for 30 days.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 2026 results and a business update on May 5, 2026. IMCIVREE generated $60.1M in global net product revenue; U.S. sales were $36.9M (61%) and international sales $23.2M (39%). FDA approved IMCIVREE for acquired hypothalamic obesity on March 19, 2026; European Commission authorized marketing for acquired HO; Japanese review is underway. Cash and short-term investments were $340.6M as of March 31, 2026. Non-GAAP operating expense guidance for 2026 is $385M–$415M.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported new pediatric data presented at the Pediatric Endocrine Society, showing longer-term setmelanotide outcomes in acquired hypothalamic obesity.
Highlights: in 10 pediatric patients completing 2.5 years, mean changes from baseline were BMI -16.4%, BMI Z-score -1.6, and %BMI95 -34.2 percentage points. Phase 3 TRANSCEND pediatric data after 1 year showed 71.1% improved ≥1 weight category.